SCHEMBL3526523

SCHEMBL3526523

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)NC(=O)OC(C)(C)C)cnc(N)c34)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 15/20 0.65
CSF1R P07333 15/20 0.65
FLT1 P17948 15/20 0.65
AURKA O14965 14/20 0.65
ABL1 P00519 14/20 0.65
FGFR1 P11362 14/20 0.65
FLT3 P36888 14/20 0.65
NEK2 P51955 14/20 0.65
ROCK1 Q13464 14/20 0.65
NTRK2 Q16620 14/20 0.65
KIT P10721 14/20 0.65
MET P08581 13/20 0.65
LYN P07948 13/20 0.65
NTRK1 P04629 12/20 0.65
MAP4K4 O95819 12/20 0.65
PTK2 Q05397 12/20 0.65
MAP4K2 Q12851 12/20 0.65
TAOK1 Q7L7X3 12/20 0.65
PLK4 O00444 12/20 0.65
RPS6KB1 P23443 12/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533150 0.92 KDR (0.61) LCKCSF1RFLT1AURKAABL1
SCHEMBL3528472 0.92 KDR (0.65) LCKCSF1RFLT1AURKAABL1
SCHEMBL3533687 0.90 LCK (0.62) LCKCSF1RFLT1AURKAABL1
SCHEMBL3529372 0.89 KDR (0.77) LCKCSF1RFLT1AURKAABL1
SCHEMBL3525625 0.88 KDR (0.79) LCKCSF1RFLT1AURKAABL1
SCHEMBL3528601 0.85 KDR (0.78) LCKCSF1RFLT1AURKAABL1
SCHEMBL3532446 0.85 KDR (0.66) LCKCSF1RFLT1AURKAABL1
SCHEMBL3530167 0.84 KDR (0.63) LCKCSF1RFLT1AURKAABL1
SCHEMBL3533342 0.84 KDR (0.63) LCKCSF1RFLT1AURKAABL1
SCHEMBL3534027 0.84 KDR (0.77) LCKCSF1RFLT1AURKAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FLT1 613/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FLT1 613/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FLT1 613/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK LCK 3/4885CSF1R 1197/4885FLT1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.